Not a healthcare professional? Visit our Public site

report_adverse_events REPORT ADVERSE EVENT Login Register notification bell

Placeholder

    Contact us REQUEST A REPRESENTATIVE

    Your browser is not supported.

    To view this content, please use one of the following browsers:

    • Microsoft Edge
    • Chrome
    • Safari
    event image
    icon_therapy_area

    ▼REZZAYO® Patient Case Study - Pharmacist Ahmad Simreekheea

    ▼REZZAYO® (rezafungin) Patient Case Study - Pharmacist Ahmad Simreekheea
    Language Icon English
    duration icon 06:22
    Event topic Icon Rezzayo formulary submission
    Antifungal
    Select Therapy Icon

    Ahmad Simreekheea

    Watch as Ahmad Simreekheea discusses his experience with using REZZAYO(R) in a patient case study.

    Ahmad Simreekheea

    Antimicrobial Pharmacist, MSc 

    Video descripton: Watch as Ahmad Simreekheea discusses his experience with using REZZAYO® in a patient case study.
    Watch Now
    Prescribing Information GB REZZAYO® (rezafungin) Prescribing Information NI REZZAYO® (rezafungin)

    Implementation of ▼REZZAYO® Rezafungin through formulary submission

    Implementation of ▼REZZAYO® Rezafungin through formulary submission
    Language Icon English
    duration icon 33.37
    Event topic Icon Rezzayo formulary submission
    Antifungal
    Select Therapy Icon

    Stephen Hughes

     Implementation of REZZAYO® through formulary submission

    Stephen Hughes

    Antimicrobial Pharmacist MPharm, MSc, MBA

    Watch as Consultant Antimicrobial Pharmacist Stephen Hughes talks about REZZAYO® and his experience with submitting for formulary at the Chelsea & Westminster NHS Trust.
    Watch Now
    Prescribing Information GB REZZAYO® (rezafungin) Prescribing Information NI REZZAYO® (rezafungin)

    Introducing ▼ REZZAYO® (rezafungin) the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults.

    Introducing ▼REZZAYO® (rezafungin) the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults.
    Language Icon English
    duration icon 27:15
    Event topic Icon Antifungal, Rezzayo
    Antifungal
    Select Therapy Icon

    Professor Tihana Bicanic Professor Oliver Cornely Professor Matteo Bassetti

    Launch webinar introducing ▼REZZAYO® (rezafungin) the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults. Consideration should be given to official guidance on the appropriate use of antifungal agents.1 Speakers Professor Tihana Bicanic, Professor Oliver Cornley and Matteo Bassetti present.

    Professor Tihana Bicanic

    Reader and Consultant in Infectious diseases at St George's University of London.
    Watch Now
    Prescribing Information GB REZZAYO® (rezafungin) Prescribing Information NI REZZAYO® (rezafungin)

    Upcoming Webinar

    Introducing ▼ REZZAYO® (rezafungin) the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults.


    27:15

    27:15

    I'M INTERESTED
    Professor Tihana Bicanic

    Speaker

    Professor Tihana Bicanic
    Reader and Consultant in Infectious diseases at St George's University of London.
    oliver

    Speaker

    Professor Oliver Cornely
    Director & Chair of Translational Research at the CECAD Institute of the University of Cologne, and Scientific Director of the Center for Clinical Trials. Clinically, he serves as Infectious Diseases Consultant at the University Hospital of Cologne, Germany.
    Professor Matteo Bassetti

    Speaker

    Professor Matteo Bassetti
    Head of the Infectious Diseases Clinic of the Policlinico San Martino University Hospital in Genoa and Professor of Infectious Diseases of the University of Genoa, Italy.
    Subscribe to Antifungal

    Reporting adverse events

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

    Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyUKandROI@mundipharma.com.